The Alliance for Children’s Therapeutics (ACT) was formed to develop better treatment options for children, faster than ever before.
ACT unites one of the nation’s top-five pediatric research institutions — Seattle Children’s Research Institute — with Kineta Inc., a leading biotechnology firm. Together, we are taking on a key problem: Only a small fraction of today’s pediatric treatments were developed for — or tested in — children. For example, the U.S. Food and Drug Administration approved 27 new medications in 2013. Just seven were approved for pediatric use that same year.
This means care teams must apply adult treatments to treat children and teens. But children’s developing minds and bodies have unique needs, and are uniquely vulnerable to medication side effects.
ACT aims to develop therapies specifically for children and teens starting with a new drug candidate, called dalazatide (formerly ShK-186), that could be a safer, more effective treatment for autoimmune diseases like lupus, multiple sclerosis and juvenile arthritis. Our goal is to quickly start a clinical research study of dalazatide in children and teens with lupus nephritis — a potentially fatal form of lupus that occurs when the disease affects the kidneys. If the drug candidate works, it will be a step toward transforming treatment for multiple sclerosis, juvenile idiopathic arthritis and other conditions that affect millions of people.
We can do it with your help. There is no federal funding available for these studies and developing better treatments requires more than expert researchers. It requires supporters who share our vision of helping children lead happier, healthier lives.